The objective of this study is to constitute cohorts of IBD versus non-IBD patients to identify (a) new biomarker(s) of intestinal dysbiosis associated with inflammatory bowel disease, and develop a prototype for assaying such marker(s) in blood.
Male or female ≥ 18 years old
Able to follow the instructions of the study
Having signed an informed consent
A confirmed diagnosis of IBD
Commercial Pharmaceutical probiotic administration within the previous month
Treatment with antibiotics (whatever the route of administration) within last 3 months
Non-remission Cancer or in remission for less than 6 months
Any contraindication to colonoscopy and/or biopsy, left to PI discretion
Parallel
biological samples collection
Procedure/SurgeryCollection of biological samples from the same cohorts: faeces, serum, intestinal biopsies
Number of patients recruited in each cohort
60 patients in IBD cohort and 60 patients in control cohort
number of faeces samples collected in each cohort
60 patients in IBD cohort and 60 patients in control cohort
Number of plasma samples collected in each cohort
60 patients in IBD cohort and 60 patients in control cohort
Number of biopsy samples collected in each cohort
60 patients in IBD cohort and 60 patients in control cohort with 4 colonic biopsies/ patient
